MediWound (NASDAQ:MDWD) Now Covered by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of MediWound (NASDAQ:MDWD) in a research report released on Monday morning. The brokerage issued an outperform rating and a $34.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on the stock. Craig Hallum initiated coverage on shares of MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 price objective on the stock. Alliance Global Partners started coverage on shares of MediWound in a research note on Friday, May 2nd. They set a “buy” rating and a $25.00 target price on the stock. Wall Street Zen raised shares of MediWound to a “sell” rating in a research note on Friday, March 21st. Finally, HC Wainwright set a $31.00 target price on shares of MediWound and gave the company a “buy” rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, MediWound presently has a consensus rating of “Moderate Buy” and an average target price of $31.80.

MediWound Stock Up 1.3%

MDWD stock opened at $22.24 on Monday. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The firm’s 50-day simple moving average is $18.00 and its 200 day simple moving average is $17.82. The stock has a market cap of $240.37 million, a PE ratio of -7.67 and a beta of 0.30.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.58. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The business had revenue of $3.96 million for the quarter, compared to analysts’ expectations of $5.20 million. During the same quarter last year, the company earned ($1.05) EPS. Equities analysts forecast that MediWound will post -2.66 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its stake in MediWound by 4.4% during the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 481 shares during the period. Corebridge Financial Inc. boosted its position in shares of MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,162 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of MediWound by 11.2% during the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 1,249 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.